Myositis Specific 11 Antibodies Panel : 1001823

Test Code
MYOSIT or 1001823

Alias/See Also
Jo-1; Mi-2; PL-7; PL-12; EJ; SRP; OJ; NXP2; MDA5; TIF1-gamma; CADM140; Autoimmune myopathy; NuRD Complex; JDM; Polymyositis; SRP Signal recognition protein AB; Necrotizing myopathy; Paraneoplastic myositis; TIF 1-gamma antibody; Dermatomyositis; Transf

CPT Codes
84182x6, 86235x5

This panel includes: Jo-1 Ab, PL-7 Ab, PL-12 Ab, EJ Ab, OJ Ab, SRP Ab, Mi-2 Alpha Ab, Mi-2 Alpha Ab, Mi-2 Beta Ab, MDA-5 Ab, TIF-1y Ab, NXP-2 Ab.

Serum separator tube.

Transport Container
Centrifuge serum separator tube and transport. 0.5 mL serum, (Min: 0.3 mL)

Transport Temperature

Specimen Stability
After separation from cells: Ambient: 7 days; Refrigerated: 14 days; Frozen: 28 days

Line Blot

Setup Schedule
Tuesday - Saturday

Report Available
4-6 days (From receipt at performing laboratory)

These tests were developed and their analytical performance characteristics have been determined by Quest Diagnostics. They have not been cleared or approved by the FDA. These assays have been validated pursuant to the CLIA regulations and are used for clinical purposes.

Reference Range
Jo-1 Ab less than 11 SI
PL-7 Ab less than 11 SI
PL-12 Ab less than 11 SI
EJ Ab less than 11 SI
OJ Ab less than 11 SI
SRP Ab less than 11 SI
Mi-2 Alpha Ab less than 11 SI
Mi-2 Beta Ab less than 11 SI
MDA-5 Ab less than 11 SI
TIF-1y Ab less than 11 SI
NXP-2 Ab less than 11 SI

Clinical Significance
Myositis-specific autoantibodies (MSAs) are highly selective, usually exclusive and are associated with particular clinical phenotypes within the myositis spectrum. Myositis-specific autoantibodies to cytoplasmic enzymes that catalyze the binding of specific amino acids to their cognate tRNA define the anti-synthetase syndrome characterized by myositis and lung inflammation, and include autoantibodies to Jo-1 (antihistidyl-tRNA synthetase), PL-7 (threonyl), PL-12 (alanyl), EJ (glycyl), and OJ (isoleucyl). A further subset of myositis patients is characterized by the presence of autoantibodies directed against the signal recognition particle (SRP). Autoantibodies to Mi-2 (Mi-2/nucleosome remodelling and deacetylase (NuRD) complex) are detected in patients with hallmark dermatomyositis features. Autoantibody to a cytoplasmic 140-kDa protein, melanoma-differentiation associated gene 5 (MDA5), also known as anti-CADM140, identified patients with clinically amyopathic dermatomyositis (CADM) and rapidly progressive lung disease. Autoantibodies to transcriptional intermediary factor 1-gamma (TIF-1 y), a p155/140 nuclear protein involved in cellular differentiation, have been reported in adult and juvenile dermatomyositis; in adults, it is associated with malignancy. Autoantibodies to nuclear matrix protein NXP-2, another 140-kDa protein, is found in juvenile dermatomyositis (JDM). Anti-TIF-1 y and anti-NXP-2, two novel serological subsets in JDM, occur collectively in >40% of children and appear to identify those with more severe disease.

Performing Laboratory
Quest Diagnostics

The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed. Any Profile/panel component may be ordered separately. Reflex tests are performed at an additional charge.